⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102355 | 1.00 | — | — | |
| SCHEMBL15894136 | 1.00 | — | — | |
| SCHEMBL9921199 | 1.00 | — | — | |
| SCHEMBL26031968 | 0.88 | PDK1 (0.32) | — | |
| SCHEMBL12292409 | 0.88 | PDK1 (0.32) | — | |
| SCHEMBL26025540 | 0.88 | PDK1 (0.32) | — | |
| SCHEMBL24996781 | 0.86 | — | — | |
| SCHEMBL25707028 | 0.83 | — | — | |
| SCHEMBL13045067 | 0.82 | ALDH1A1 (0.32) | — | |
| SCHEMBL21722594 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230332143-A1 | RNA-Editing Oligonucleotides and Uses Thereof | KORRO BIO, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323363-A1 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-10-12 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295614-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL) | KORRO BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | BANK OF AMERICA, N.A. | 2023-09-14 | — | — | US | disclosed |
| US-20230287432-A1 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230257745-A1 | Circular siRNAs | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230193284-A1 | TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-06-22 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230174989-A1 | Methods and Compositions for the ADAR-Mediated Editing of ABCA4 | KORRO BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11015201-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210095290-A1 | ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2021-04-01 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |